TAG ARCHIVES FOR minimal risk

16
Mar2020

Pediatric subjects participating in HHS-funded or FDA-regulated studies are afforded additional protections not codified in subpart A of the Federal Policy for the Protection of Human Subjects (the Common Rule). On September 18, 2019, PRIM&R hosted a webinar, Pediatric Risk Determination: IRB Considerations and Cases. Presented by Rich Gormon, MD, and Donna L. Snyder, MD, this webinar helped attendees understand pediatric subpart D regulations, identify criteria for pediatric approvable research, and evaluate if the interventions or procedures in a protocol hold the prospect of direct benefit. After the webinar, the speakers responded to attendee questions time didn’t permit us to address live. We’re pleased to share those responses with the readers of Ampersand. Read more

5
Feb2019

PRIM&R recently submitted comments in response to the Food and Drug Administration (FDA)’s proposed rule "Institutional Review Board Waiver or Alteration of Informed Consent for Minimal Risk Clinical Investigations," which was published in the Federal Register on November 15, 2018. Comments are due February 13. Read more

7
May2018

At the 2017 AER conference, I caught the plenary session, “New Frontiers: The Changing Landscape of Research Regulations.” One of the presenters, John R. Baumann, PhD, the Associate Vice President for Research Compliance at Indiana University, shared with us how his institution was approaching the upcoming changes to the Common Rule, including the elimination of continuing review. Read more

1
Aug2017

In June 2017, PRIM&R hosted the webinar series Focus on the Revised Common Rule. Comprising four sessions on the topics of informed consent, exemptions and types of review, biospecimens and identifiable private information, and implications for social, behavioral, and educational research (SBER), these webinars provided a close look at the most significant areas of change described in the revised Common Rule. This is Part I of a two-part series. Read more

12
Mar2014

by David R. Van Houten, MS, research integrity advocate

During PRIM&R’s Best Practices for Assessing Risk in Social and Behavioral Research webinar, Jeffrey M. Cohen, PhD, CIP, CEO of HRP Consulting Group, Inc., discussed challenges for institutional review boards (IRBs) charged with reviewing social and behavioral research.

While human research protections is complicated across all areas of research, the presentation served to illuminate the complexities associated with protecting human subjects in social and behavioral studies. In his presentation, Dr. Cohen pointed out that IRB [...] Read more